"In response to questions on flatlining on Alemtuzumab. The following is a graph from a poster I presented at the American Academy of Neurology meeting in San Diego earlier this year. You can see that you are more than twice as likely to remain stable or improve in disability when treated with Alemtuzumab compared to interferon-beta. This refers to 2 years follow-up. However, we know that in the vast majority this effect persists for up to 5 years and probably longer. Alemtuzumab is not for everyone; you need to understand the risks and benefits of treatment and the risks of MS."
CoI: multiple